Skystar Bio-Pharmaceutical Company Announces Receipt of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Notification Letter

XI'AN, CHINA--(Marketwired - Oct 23, 2015) -  Skystar Bio-Pharmaceutical Company ( NASDAQ : SKBI ), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced today that on October 20, 2015 it received a letter from NASDAQ Stock Market indicating that that Skystar failed to comply with Nasdaq's filing requirement set forth in Listing Rule 5250(c)(1) (the "Rule") because it failed to file its Form 10-K for the fiscal year ended December 31, 2014, and Forms 10-Q for the periods ended March 31, and June 30, 2015, respectively (together, the "Delinquent Reports").

Based on its review of the materials submitted by Skystar (together, the "Submissions"), Nasdaq's staff granted Skystar an exception until October 12, 2015, to file the Delinquent Reports and thereby regain compliance with the Rule (the "Exception"). The notification letter indicated that because the Company has not filed the Delinquent Reports and does not meet the terms of the Exception.

Nasdaq also notified Skystar of two additional, and separate, bases for delisting under Listing Rule 5250(b)(1) (failure to disclose material non-public information) and Listing Rule 5101 (public interest concerns). The information to which Nasdaq referred was the conduct by Skystar's audit committee of an internal investigation into certain allegations, raised by Skystar's auditors, that the auditors had been presented by Skystar personnel with false bank documents relating to one bank account. The public interest concerns arise from the audit committee's determination that a low level employee had falsified bank documents relating to one bank account, which were then provided to the auditors by other Skystar personnel who were unaware of the falsehood. The employee who falsified the document is no longer with Skystar. After the audit committee concluded its investigation, the Company's external auditors have resumed their audit of Skystar's financial statements for the year ended December 31, 2014. Nasdaq's notice indicated that all of the foregoing constituted a basis for delisting by Nasdaq.

NASDAQ Delisting Action

Skystar intends to request a review of the delisting determination by NASDAQ's Listing Qualifications Panel. The hearing is generally scheduled approximately 30-45 days after the date of the hearing request. Unless Skystar files a request for a hearing, Skystar's common stock will be suspended from trading on October 29, 2015. A request for a hearing regarding a delinquent filing will stay the suspension for a period of 15 days from the date of the request. Pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, when Skystar requests a hearing, Skystar will request a stay of the suspension, pending the hearing. A Panel will review the request for an extended stay and notify Skystar of its conclusion as soon as is practicable but in any event no later than 15 calendar days following the deadline to request the hearing. Skystar will inform the public of the conclusion of the Panel and subsequent hearing date.

About Skystar Bio-Pharmaceutical Company

Skystar is a China-based developer, manufacturer and distributor of veterinary healthcare and medical care products. Skystar has four product lines: veterinary medicines, probiotics, vaccines and feed additives formulated and packaged in house across several modern manufacturing and distributions facilities. Skystar's distribution network includes almost 3,000 distribution agents of which 360 are franchised stores with exclusivity agreements covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com .

Safe Harbor Statements

When used in this release, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, without limitation, the Company's ability to complete its IgG kit effort as well as other related efforts at the Huxian facilities, the Company's ability to timely, effectively and accurately assess the efficacy and commercial potential of any technologies that may results from such R&D efforts, the Company's ability to timely and effectively commercialize any such technologies. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact: Skystar Bio-Pharmaceutical Company Scott Cramer Director - Corporate Development & U.S. Representative (407) 645-4433

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 264

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 317

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 367

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 414

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 217

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 238

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 121

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Elanco Secures FDA EUA for Credelio in Fighting NWS in Dogs

Updated Category News Views 275

Elanco's Innovative Step Against New World Screwworm Elanco Animal Health Incorporated (NYSE: ELAN) has achieved a significant milestone, receiving the first Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its product, Credelio™ (lotilaner), designed to treat infestations of New World Screwworm (NWS) in dogs. This groundbreaking...

Continue Reading
Hillary Ashton Sells Teradata Shares: Insights and Implications

Updated Category News Views 412

Hillary Ashton’s Sale of Teradata Shares: A Closer Look In an important insider transaction, Hillary Ashton, who is the Chief Product Officer at Teradata (TDC), recently sold 14,962 shares of the company's stock. This sale brought in a total of $411,903, as revealed in a recent SEC filing that highlights insider activity within the company. Currently, Teradata's stock...

Continue Reading
Legal Updates for Investors of Humana Inc. Amid Lawsuit

Updated Category News Views 158

Understanding the Ongoing Lawsuit Against Humana Inc. Investors focusing on the recent activities surrounding Humana Inc. (NYSE: HUM) should be aware of a significant lawsuit that has implications for individuals who acquired shares prior to July 2022. The Shareholders Foundation, Inc. has provided updates concerning the ongoing legal proceedings relevant to these...

Continue Reading
Empowering Local Job Seekers: The Trimborns of AtWork Tampa

Updated Category News Views 231

AtWork Opens New Storefront in Tampa, Florida AtWork, a prominent staffing franchise known for empowering job seekers and fostering company growth, has expanded its presence with a new location in Tampa. This strategic establishment at 8402 Laurel Fair Circle, Suite 101, stands across the Florida State Fairgrounds, ready to cater to the needs of the local workforce. Meet...

Continue Reading
Investor Claims Wall Street is Collapsing Cryptocurrency Values

Updated Category News Views 227

Investor Claims Wall Street is Collapsing Cryptocurrency Values Mike Alfred, a noted investor and proponent of Bitcoin, has raised significant concerns regarding potential manipulation of the cryptocurrency markets by major Wall Street players. He believes that these entities are actively working to drive down Bitcoin prices specifically to pressure companies like...

Continue Reading